In the validating cohort, patients with M1 and M6 disease were more likely to have MAPKBP1high in the FAB subtype (P = 0.001, P = 0.00284, respectively).We also found that MAPKBP1high patients with CN-AML were more likely to have a higher expression of ERG1, MN1, WT1, DNMT3B and TCF4 (P < 0.001, P = 0.028, P < 0.001, P < 0.001, and P < 0.001, respectively) and low LEF1 (P < 0.001) compared with MAPKBP1low patients (supplemental Table S1). Here, DNMT3B is linked to acute myeloid leukemia.